Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

Michal Harel, Rona Ortenberg, Siva Karthik Varanasi, Kailash Chandra Mangalhara, Mariya Mardamshina, Ettai Markovits, Erez N. Baruch, Victoria Tripple, May Arama-Chayoth, Eyal Greenberg, Anjana Shenoy, Ruveyda Ayasun, Naama Knafo, Shihao Xu, Liat Anafi, Gali Yanovich-Arad, Georgina D. Barnabas, Shira Ashkenazi, Michal J. Besser, Jacob SchachterMarcus Bosenberg, Gerald S. Shadel, Iris Barshack, Susan M. Kaech, Gal Markel*, Tamar Geiger

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Proteomic profiling of melanomas from patients undergoing immunotherapy reveals key mediators of tumor immunogenicity.

Original languageEnglish
Pages (from-to)236-250.e18
JournalCell
Volume179
Issue number1
DOIs
StatePublished - 19 Sep 2019

Funding

FundersFunder number
Israel Innovation Authority
Lemelbaum family
NOMIS Center Postdoctoral Foundation
Samueli Foundation
National Institutes of HealthR01 CA216102
National Cancer InstituteP01CA128814
Melanoma Research Alliance
National Cancer Center

    Keywords

    • anti-PD-1
    • cancer metabolism
    • immune checkpoint inhibitors
    • immunotherapy
    • lipid metabolism
    • mass spectrometry
    • melanoma
    • mitochondrial metabolism
    • proteomics
    • tumor-infiltrating lymphocytes

    Fingerprint

    Dive into the research topics of 'Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence'. Together they form a unique fingerprint.

    Cite this